Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | USP1 | O94782 | 8/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481841 | 1.00 | FYN (0.56) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL481931 | 1.00 | FYN (0.56) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL977398 | 0.85 | FYN (0.54) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL977396 | 0.85 | FYN (0.54) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL976284 | 0.84 | FYN (0.53) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL976283 | 0.84 | FYN (0.53) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL975509 | 0.84 | FYN (0.72) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL482134 | 0.83 | FYN (0.63) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL482133 | 0.83 | FYN (0.63) | FYNUSP1MTORJAK2JAK3 | |
| SCHEMBL977020 | 0.82 | FYN (0.59) | FYNUSP1MTORJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | claimed |
| EP-2995619-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS COMPRISING IMIDAZOPYRIMIDINES | Cytokinetics, Inc. (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2666777-A1 | Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods | Cytokinetics, Inc. (US) | 2013-11-27 | — | — | EP | claimed |
| EP-2583970-A1 | Certain chemical entities, compositions and methods comprising imidazopyrimidines | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-04-15 | — | — | US | claimed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | claimed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | claimed |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYTOKINETICS, INCORPORATED (US) | 2020-09-08 | — | — | US | disclosed |
| EP-2995619-B1 | CERTAIN CHEMICAL ENTITIES COMPRISING IMIDAZOPYRIMIDINES, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | CYTOKINETICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | CYTOKINETICS INC (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2069352-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2008-06-19 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008016669-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266192-A1 | METHODS FOR IMPROVING DIAPHRAGM FUNCTION | TNNC1, TNNI3, DIAPH1 | FYN 1007/4885USP1 924/4885MTOR 4448/4885 |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | FYN 645/4885USP1 2197/4885MTOR 414/4885 |
| US-20080146561-A1 | Certain chemical entities, compositions and methods | TNNC1, TNNI3, TNNT2 | FYN 1580/4885USP1 2391/4885MTOR 607/4885 |
| US-10766899-B2 | Methods for preparing substituted imidazo[4,5-b]pyrazines | CYP4B1, CYP3A5, CYP4F12 | FYN 2324/4885USP1 4059/4885MTOR 3297/4885 |
| US-20190167676-A1 | METHODS FOR IMPROVING RESISTANCE TO SKELETAL MUSCLE FATIGUE | TNNC1, TNNI3, TNNT2 | FYN 2763/4885USP1 640/4885MTOR 3118/4885 |
| US-20100093741-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | FYN 1580/4885USP1 2391/4885MTOR 607/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | FYN 116/4885USP1 2531/4885MTOR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.